Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 379

1.

Two controls of cell proliferation underlie cancer relapse.

Pardee AB, Li CJ.

J Cell Physiol. 2018 May 31. doi: 10.1002/jcp.26597. [Epub ahead of print]

PMID:
29851079
2.

Bioregulation.

Pardee AB.

J Cell Physiol. 2015 Dec;230(12):2898-902. doi: 10.1002/jcp.25059. Review.

PMID:
26031897
3.

Suppression of cancer relapse and metastasis by inhibiting cancer stemness.

Li Y, Rogoff HA, Keates S, Gao Y, Murikipudi S, Mikule K, Leggett D, Li W, Pardee AB, Li CJ.

Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44. doi: 10.1073/pnas.1424171112. Epub 2015 Jan 20.

4.

The pursuit of oncotargets through understanding defective cell regulation.

Qiao M, Shi Q, Pardee AB.

Oncotarget. 2010 Nov;1(7):544-51. Review.

5.

A need for basic research on fluid-based early detection biomarkers.

Martin KJ, Fournier MV, Reddy GP, Pardee AB.

Cancer Res. 2010 Jul 1;70(13):5203-6. doi: 10.1158/0008-5472.CAN-10-0987. Epub 2010 Jun 29. Review.

6.

Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis.

Qiao M, Wang Y, Xu X, Lu J, Dong Y, Tao W, Stein J, Stein GS, Iglehart JD, Shi Q, Pardee AB.

Mol Cell. 2010 May 28;38(4):512-23. doi: 10.1016/j.molcel.2010.03.017.

7.

Metastasis and AKT activation.

Sheng S, Qiao M, Pardee AB.

J Cell Physiol. 2009 Mar;218(3):451-4. doi: 10.1002/jcp.21616. Review.

PMID:
18988188
8.

Metastasis and AKT activation.

Qiao M, Sheng S, Pardee AB.

Cell Cycle. 2008 Oct;7(19):2991-6. Epub 2008 Oct 13. Review.

PMID:
18818526
9.

A devious cube of cancer.

Pardee AB, Qiao M.

J Cell Physiol. 2008 Jul;216(1):1-2. doi: 10.1002/jcp.21425. No abstract available.

PMID:
18338337
10.

Differential display of mRNA by PCR.

Liang P, Pardee AB.

Curr Protoc Mol Biol. 2001 Nov;Chapter 25:Unit 25B.3. doi: 10.1002/0471142727.mb25b03s56.

PMID:
18265216
11.

Biomarkers, regerons, and pathways to lethal cancer.

Qiao M, Pardee AB.

J Cell Biochem. 2007 Dec 1;102(5):1076-86. Review.

PMID:
17957698
12.
13.

Metastatic potential of 21T human breast cancer cells depends on Akt/protein kinase B activation.

Qiao M, Iglehart JD, Pardee AB.

Cancer Res. 2007 Jun 1;67(11):5293-9.

14.
15.

Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine.

Bai VU, Kaseb A, Tejwani S, Divine GW, Barrack ER, Menon M, Pardee AB, Reddy GP.

Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2343-8. Epub 2007 Feb 5.

16.

Tumor progression--targets for differential therapy.

Pardee AB.

J Cell Physiol. 2006 Dec;209(3):589-91. Review.

PMID:
17001691
17.

Regulatory molecular biology.

Pardee AB.

Cell Cycle. 2006 Apr;5(8):846-52. Epub 2006 Apr 17. Review.

PMID:
16552190
18.
19.

Cancer chemotherapy by deoxynucleotide depletion and E2F-1 elevation.

Wang A, Li CJ, Reddy PV, Pardee AB.

Cancer Res. 2005 Sep 1;65(17):7809-14.

20.

Crossroads of estrogen receptor and NF-kappaB signaling.

Biswas DK, Singh S, Shi Q, Pardee AB, Iglehart JD.

Sci STKE. 2005 Jun 14;2005(288):pe27. Review.

PMID:
15956359
21.

Regulation in S phase by E2F.

Pardee AB, Li CJ, Reddy GP.

Cell Cycle. 2004 Sep;3(9):1091-4. Epub 2004 Sep 4. Review.

PMID:
15467444
22.

NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis.

Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehart JD.

Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10137-42. Epub 2004 Jun 25.

23.

Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF-kappaB as a target.

Monks NR, Biswas DK, Pardee AB.

J Cell Biochem. 2004 Jul 1;92(4):646-50. Review.

PMID:
15211562
24.

Ruth Sager.

Pardee AB.

Biogr Mem Natl Acad Sci. 2001;80:276-89. No abstract available.

PMID:
15202472
25.

Rambling thoughts about doing and thinking research.

Pardee AB.

Cancer Biol Ther. 2004 Jun;3(6):573-7. Epub 2004 Jun 18. No abstract available.

PMID:
15118417
26.

Analysing differential gene expression in cancer.

Liang P, Pardee AB.

Nat Rev Cancer. 2003 Nov;3(11):869-76. doi: 10.1038/nrc1214. Review. No abstract available.

PMID:
14668817
27.

Apoptosis in non-proliferating cells: implications for viral infection and tumourigenesis.

Borodyansky L, Li YZ, Pardee AB, Li CJ.

Apoptosis. 1998 Dec;3(6):381-5.

PMID:
14646470
28.

Beginnings of feedback inhibition, allostery, and multi-protein complexes.

Pardee AB, Reddy GP.

Gene. 2003 Dec 4;321:17-23. Review. No abstract available.

PMID:
14636988
29.

Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents.

Keyomarsi K, Pardee AB.

Prog Cell Cycle Res. 2003;5:527-32. Review.

PMID:
14593747
30.

Normal cells arrest cancer cells in G2.

Pardee AB.

Cell Cycle. 2003 Sep-Oct;2(5):454. Review. No abstract available.

PMID:
12963842
31.

Evidence for defective retinoid transport and function in late onset Alzheimer's disease.

Goodman AB, Pardee AB.

Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2901-5. Epub 2003 Feb 25. Review.

32.

Selective killing of cancer cells by beta -lapachone: direct checkpoint activation as a strategy against cancer.

Li Y, Sun X, LaMont JT, Pardee AB, Li CJ.

Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2674-8. Epub 2003 Feb 21.

33.

Apoptosis caused by chemotherapeutic inhibition of nuclear factor-kappaB activation.

Biswas DK, Martin KJ, McAlister C, Cruz AP, Graner E, Dai SC, Pardee AB.

Cancer Res. 2003 Jan 15;63(2):290-5.

34.

Role reversal for anticancer agents.

Pardee AB.

Cancer Biol Ther. 2002 Jul-Aug;1(4):426-7. No abstract available.

PMID:
12432260
35.

The restriction point of the cell cycle.

Blagosklonny MV, Pardee AB.

Cell Cycle. 2002 Mar-Apr;1(2):103-10. Review.

PMID:
12429916
36.

PaJaMas in Paris.

Pardee AB.

Trends Genet. 2002 Nov;18(11):585-7.

PMID:
12414189
37.

Sensitive assays for detection of lung cancer. Molecular markers in blood samples.

Fournier MV, Martin KJ, Graner E, Pardee AB.

Methods Mol Med. 2003;75:239-50. No abstract available.

PMID:
12407744
38.

Cancer therapy with beta-lapachone.

Pardee AB, Li YZ, Li CJ.

Curr Cancer Drug Targets. 2002 Sep;2(3):227-42. Review.

PMID:
12188909
39.

Regulation, restriction, and reminiscences.

Pardee AB.

J Biol Chem. 2002 Jul 26;277(30):26709-16. Epub 2002 Jun 5. No abstract available.

40.

Conceptual biology: unearthing the gems.

Blagosklonny MV, Pardee AB.

Nature. 2002 Mar 28;416(6879):373. No abstract available.

PMID:
11919607
41.

Expression of cyclins E1 and E2 during mouse development and in neoplasia.

Geng Y, Yu Q, Whoriskey W, Dick F, Tsai KY, Ford HL, Biswas DK, Pardee AB, Amati B, Jacks T, Richardson A, Dyson N, Sicinski P.

Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13138-43. Epub 2001 Oct 30.

42.

Solid tumor cancer markers and applications to steroid hormone research.

Fournier MV, Martin KJ, Pardee AB.

Methods Mol Biol. 2001;176:329-40. Review. No abstract available.

PMID:
11554333
43.

The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers.

Biswas DK, Dai SC, Cruz A, Weiser B, Graner E, Pardee AB.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10386-91. Epub 2001 Aug 21.

44.

A therapeutic target for hormone-independent estrogen receptor-positive breast cancers.

Biswas DK, Cruz A, Pettit N, Mutter GL, Pardee AB.

Mol Med. 2001 Jan;7(1):59-67.

45.
46.

Exploiting cancer cell cycling for selective protection of normal cells.

Blagosklonny MV, Pardee AB.

Cancer Res. 2001 Jun 1;61(11):4301-5. Review.

47.

High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood.

Martin KJ, Graner E, Li Y, Price LM, Kritzman BM, Fournier MV, Rhei E, Pardee AB.

Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2646-51. Epub 2001 Feb 20.

49.
50.

Detection of the level of estrogen receptor and functional variants in human breast cancers by novel assays.

Biswas DK, Cruz AP, Pardee AB.

Biotechniques. 2000 Nov;29(5):1056-60, 1062-4.

PMID:
11084868

Supplemental Content

Loading ...
Support Center